Michael Chi Sells 14,027 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer owned 432,124 shares of the company’s stock, valued at $13,611,906. This trade represents a 3.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Hims & Hers Health Trading Up 11.1%

HIMS stock opened at $35.44 on Friday. The business has a fifty day moving average price of $26.42 and a 200 day moving average price of $26.58. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The stock has a market capitalization of $8.20 billion, a price-to-earnings ratio of -393.79, a P/E/G ratio of 45.59 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.05 EPS for the current fiscal year.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Barclays raised its price target on Hims & Hers and maintained a bullish stance, reinforcing optimism around accelerating growth and margin improvement tied to the Novo Nordisk partnership. Hims & Hers Stock Jumps After Barclays Raises Price Target
• Positive Sentiment: Analysts and commentators see the company as a potential beneficiary of the peptide/GLP-1 market and an upcoming FDA review, which may provide a new catalyst for future growth. HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
• Positive Sentiment: Bullish coverage argues that international expansion and the renewed partnership with Novo Nordisk support Hims & Hers’ long-term revenue and EBITDA targets. Hims & Hers: The Bull Case Remains Strong
• Neutral Sentiment: Insider selling by Irene Becklund and COO Michael Chi was disclosed, but both transactions were tied to pre-arranged 10b5-1 plans and equity-award tax withholding, which makes the signal less concerning for investors. SEC filing for Michael Chi sale
• Negative Sentiment: Recent commentary still points to weak prior-quarter fundamentals, including modest revenue growth, declining margins, and a net loss, reminding investors that execution risk remains. Hims & Hers: The Bull Case Remains Strong

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Morgan Stanley lowered their price objective on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. JPMorgan Chase & Co. decreased their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Canaccord Genuity Group set a $32.00 price target on shares of Hims & Hers Health in a report on Tuesday, May 12th. Truist Financial upped their price objective on Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, May 22nd. Finally, Citigroup increased their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $29.37.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares during the last quarter. Capital World Investors grew its holdings in Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock worth $1,065,399,000 after acquiring an additional 223,892 shares during the period. Farallon Capital Management LLC grew its holdings in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares during the period. State Street Corp raised its position in shares of Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after acquiring an additional 132,311 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Hims & Hers Health by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after purchasing an additional 608,950 shares during the period. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.